In vitro activity of uva-ursi against cytochrome P450 isoenzymes and P-glycoprotein

Canadian Journal of Physiology and Pharmacology

Volumn 85, Issue 11, 2007, Pages 1099-1107

  Chauhan, B ^a   Yu, C ^a   Krantis, A ^a   Scott, I ^a   Arnason, J T ^a   Marles, R J ^b   Foster, B C ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b HEALTH CANADA   (Canada)

Author keywords

3A4; Bearberry; Caco 2; Cytochrome P450; Drug interactions; Macrophages; Metabolism; Natural health products; P glycoprotein; Rhodamine 123; Uva ursi

Indexed keywords

ARBUTIN; ARCTOSTAPHYLOS UVA URSI EXTRACT; AROMATASE; BIOLOGICAL MARKER; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; CYTOCHROME P450 ISOENZYME; GALLIC ACID; ISOQUERCETIN; METHANOL EXTRACTION RESIDUE; MULTIDRUG RESISTANCE PROTEIN 1; MYRICETIN 3 RHAMNOSIDE; RHODAMINE 123; UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; ARCTOSTAPHYLOS UVA URSI; ARTICLE; BIOASSAY; CELL STRAIN CACO 2; DRUG CAPSULE; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOCYTE; PRIORITY JOURNAL; PROTEIN TRANSPORT;

ARCTOSTAPHYLOS; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; ISOENZYMES; P-GLYCOPROTEIN; PLANT EXTRACTS;

EID: 38849134041     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/Y07-106     Document Type: Article

References (31)

1. Brinker, F. 1998. Herb Contraindications and drug interactions. 2nd ed. Eclectic Medical Publications, Sandy, Oregon, USA. p. 35.
2. Brooks, S. (Editor). 1995. Botanical toxicology. Protocol. J. Botan. Med. 1(1):147-158.
3. Cordon-Cardo, C., O'Brien, J.P., Casals, D., Rittman-Grauer, L., Biedler, J.L., Melamed, M.R., and Bertino, J.R. 1989. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. U.S.A. 86: 695-698. doi:10.1073/pnas.86.2.695.
4. Dietrich, C.G., Geier, A., and Oude Elferink, R.P. 2003. ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut, 52: 1788-1795. doi:10.1136/gut.52.12.1788.
5. Du, L., Hoffman, S.M., and Keeny, D.S. 2004. Epidermal CYP2 family cytochromes P450. Toxicol. Appl. Pharmacol. 195: 278-287. doi:10.1016/j.taap.2003.09.020.
6. Foster, B.C., Foster, M.S., Vandenhoek, S., Krantis, A., Budzinski, J.W., Arnason, J.T., Gallicano, K.D., and Choudri, S. 2001. An in vitro evaluation of human cytochrome P450 3A4 and Pglycoprotein inhibition by garlic. J. Pharm. Pharm. Sci. 4: 176-184.
7. Geick, A., Eichelbaum, M., and Burk, O. 2001. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem. 276: 14581-14587. doi:10.1074/jbc.M010173200.
8. Glockl, I., Blaschke, G., and Vei, M. 2001. Validated methods for direct determination of hydroquinone glucuronide and sulfate in human urine after oral intake of bearberry leaf extract by capillary zone electrophoresis. J. Chromatogr. B Biomed. Sci. Appl. 761: 261-266. doi:10.1016/S0378-4347(01) 00322-X.
9. Hennessy, M., Kelleher, D., Spiers, J.P., Barry, M., Kavanagh, P., Back, D., Mulcahy, F., and Feely, J. 2002. St Johns Wort increases expression of P-glycoprotein: implications for drug interactions. Br. J. Clin. Pharmacol. 53: 75-82. doi:10.1046/j.0306-5251.2001.01516.x.
10. Hodek, P., Trefil, P., and Stiborovà, M. 2002. Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chem. Biol. Interact. 139: 1-21. doi:10.1016/S0009-2797(01)00285-X.
11. Jahodar, L., Leifertova, I., and Lisa, M. 1978. Investigation of iridoid substances in Arctostaphylos uva-ursi. Pharmazie, 33: 536-557.
12. Jellin, J.M. (Editor). 2004. Uva Ursi [online]. Natural Medicines Comprehensive Database [online]. Available from http://www.naturaldatabase.com [accessed 3 September 2006].
13. Kubo, M., Ito, M., Nakata, H., and Matsuda, H. 1990. Pharmacological studies on leaf of Arctostaphylos uva-ursi (L.) Spreng. I. Combined effect of 50% methanolic extract from Arctostaphylos uva-ursi (L.) Spreng. (bearberry leaf) and prednisolone on immuno-inflammation. Yakugaku Zasshi, 110: 59-67.
14. Latte, K.P., and Kolodziej, H. 2000. Antifungal effects of hydrolysable tannins and related compounds on dermatophytes, mould fungi and yeasts. Z. Naturforsch. (C), 55: 467-472.
15. Matsuda, H., Nakata, H., Tanaka, T., and Kubo, M. 1990. Pharmacological study on Arctostaphylos uva-ursi (L.) Spreng. II. Combined effects of arbutin and prednisolone or dexamethazone on immuno-inflammation. Yakugaku Zasshi, 110: 68-76.
16. Matsuda, H., Tanaka, T., and Kubo, M. 1991. Pharmacological studies on leaf of Arctostaphylos uva-ursi (L.) Spreng. III. Combined effect of arbutin and indomethacin on immunoinflammation. Yakugaku Zasshi, 111: 253-258.
17. Matsuda, H., Nakamura, S., Tanaka, T., and Kubo, M. 1992. Pharmacological studies on leaf of Arctostaphylos uva-ursi (L.) Spreng. V. Effect of water extract from Arctostaphylos uva-ursi (L.) Spreng. (bearberry leaf) on the antiallergic and antiinflammatory activities of dexamethasone ointment. Yakugaku Zasshi, 112: 673-677.
18. Paine, M.F., Hart, H.L., Ludington, S.S., Haining, R.L., Rettie, A.E., and Zeldin, D.C. 2006. The human intestinal cytochrome P450 "pie". Drug Metab. Dispos. 34: 880-886. doi:10.1124/dmd.105.008672.
19. Panaiotov, P. 1951. Effect in vitro of bearberry leaves extract, comparing with certain antibiotics and sulfonamides, on microorganisms found in the urinary tract. Izv. Mikrobiol. Inst. (Sofia), 2: 111-116.
20. Parejo, I., Viladomat, F., Bastida, J., and Codina, C. 2001. A single extraction step in the quantitative analysis of arbutin in bearberry (Arctostaphylos uva-ursi) leaves by high-performance liquid chromatography. Phytochem. Anal. 12: 336-339. doi:10.1002/pca.602.
21. Pizzorno, J. 1999. The textbook of natural medicine. 2nd ed. Churchill Livingstone, New York, NY.
22. Riancho, J.A., Zarrabeitia, M.T., Valero, C., Sanudo, C., Hernandez, J.L., Amado, J.A., Zarrabeitia, A., and Gonzalez-Macias, J. 2005. Aromatase gene and osteoporosis: relationship of ten polymorphic loci with bone mineral density. Bone, 36: 917-925. doi:10.1016/j.bone.2005.01.004.
23. Romiti, N., Tramonti, G., Donati, A., and Chieli, E. 2004. Effects of grapefruit juice on the multidrug transporter P-glycoprotein in the human proximal tubular cell line HK-2. Life Sci. 76: 293-302. doi:10.1016/j.lfs.2004.06.015.
24. Shimizu, M., Shiota, S., Mizushima, T., Ito, H., Hatano, T., Yoshida, T., and Tsuchiya, T. 2001. Marked potentiation of activity of beta-lactams against methicillin-resistant Staphylococcus aureus by corilagin. Antimicrob. Agents Chemother. 45: 3198-3201. doi:10.1128/AAC.45.11.3198-3201.2001.
25. Shiota, S., Shimizu, M., Sugiyama, J., Morita, Y., Mizushima, T., and Tsuchiya, T. 2004. Mechanisms of action of corilagin and tellimagrandin I that remarkably potentiate the activity of beta-lactams against methicillin-resistant Staphylococcus aureus. Microbiol. Immunol. 48: 67-73.
26. Simpson, E.R., Michael, M.D., Agarwal, V.R., Hinshelwood, M.M., Bulun, S.E., and Zhao, Y. 1997. Expression of the CYP19 (aromatase) gene: an unusual case of alternative promoter usage. FASEB J. 11: 29-36.
27. Tateishi, T., Watanabe, M., Moriya, H., Yamaguchi, S., Sato, T., and Kobayashi, S. 1999. No ethnic differences between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins. Biochem. Pharmacol. 57: 935-939. doi:10.1016/S0006-2952(98)00375-X.
28. van Heeswijk, R.P., Veldkamp, A.I., Mulder, J.W., Meenhorst, P.L., Lange, J.M., Beijnen, J.H., and Hoetelmans, R.M. 2001. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antivir. Ther. 6: 201-229.
29. Wang, L., and Del Priore, L.V. 2004. Bull's-eye maculopathy secondary to herbal toxicity from uva ursi. Am. J. Ophthalmol. 137: 1135-1137. doi:10.1016/j.ajo.2004.01.004.
30. Wrighton, S.A., Brian, W.R., Sari, M.A., Iwasaki, M., Guengerich, F.P., Raucy, J.L., Molowa, D.T., and Vandenbranden, M. 1990. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol. 38: 207-213.
31. Yarnell, E. 2002. Botanical medicines for the urinary tract. World J. Urol. 20: 285-289.